It’s a bad time for Big Pharma in India. First the Intellectual Property Appellate Board upheld the first ever compulsory licence handed out to NATCO to sell Bayer’s blockbuster cancer drug Nexavar, then another company …
The South African government must follow the lead of its BRICS peers like India and China to ensure that life-saving medicines are affordable, said Doctors without Borders (or Medecins Sans Frontieres), an international …
That the compulsory licence verdict in favour of NATCO Pharma would change the landscape of the pharma industries the world over was never in doubt. The verdict was hailed as ‘revolutionary’, ‘path-breaking’ and hailed as …
India is a ‘hip and happening country’ when it comes to litigations in the pharmaceutical and biotechnology sectors, said a leading patent attorney said on Thursday. ‘I can definitely say that India is a happening country …
In what has been billed as landmark ruling the Intellectual Property Appellate Board upheld the country’s first compulsory licence to NATCO Pharma for Bayer’s cancer drug Nexavar recently. In layman language, NATCO, an Indian …
Compulsory licences are here to stay. The Intellectual Property Appellate Board (IPAB) on Monday upheld the country’s first compulsory licence to the Hyderabad based NATCO Pharma for Bayer’s cancer drug Nexavar setting a …
Recent media reports suggest that the government has appointed a panel to look into issues relating to compulsory licensing of three cancer drugs - Trastuzumab, Ixabepilone and Dasatinib. The health ministry has sent its proposal …
